Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorRigshospitalet, Denmark

About this trial

The aim of this trial is to test whether postoperative antibiotics targeted towards bacteria in the urine can reduce the risk of infection after surgical removal of the bladder (cystectomy) compared to a standardised antibiotic prophylaxis.

Participants undergoing cystectomy will be randomly assigned to postoperatively receive (A) a standardised orally administered antibiotic prophylaxis currently given at Rigshospitalet, Copenhagen or (B) a conventional orally administered antibiotic prophylaxis targeting bacteria found in the urine postoperatively.

The investigators' hypothesis is that the targeted prophylactic antibiotic strategy will reduce the number of infection-related readmissions within 90 days of surgery compared to the standardised prophylaxis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age at surgery ≥ 18 years

Ability to understand and sign an informed consent

Malignant or benign indication for undergoing cystectomy

Planned ileal conduit as urinary diversion

Disqualifiers

Previous severe allergic reaction to antimicrobial treatment

Long-term prophylactic antibiotic treatment which is expected to be continued after the cystectomy

Trial design

Design model

Parallel

Treatments tested in this trial

  • Pivmecillinam

    Drug

    Orally administered pivmecillinam 400mg

  • Pivmecillinam

    Drug

    Orally administered targeted antimicrobial prophylaxis based on a urine culture.

  • Amoxicillin clavulanic acid

    Drug

    Orally administered targeted antimicrobial prophylaxis based on a urine culture.

  • Amoxicillin

    Drug

    Orally administered targeted antimicrobial prophylaxis based on a urine culture.

  • Cefuroxime

    Drug

    Orally administered targeted antimicrobial prophylaxis based on a urine culture.

  • Ciprofloxacin

    Drug

    Orally administered targeted antimicrobial prophylaxis based on a urine culture.

  • Linezolid

    Drug

    Orally administered targeted antimicrobial prophylaxis based on a urine culture.

  • Nitrofurantoin

    Drug

    Orally administered targeted antimicrobial prophylaxis based on a urine culture.

  • Trimethoprim

    Drug

    Orally administered targeted antimicrobial prophylaxis based on a urine culture.

  • Sulfamethoxazole trimethoprim

    Drug

    Orally administered targeted antimicrobial prophylaxis based on a urine culture.

  • Fluconazole

    Drug

    Orally administered targeted antimicrobial prophylaxis based on a urine culture.

Treatment groups

248 Participants
are divided into 2 treatment groups
Group A: Targeted antimicrobial prophylaxisExperimental treatment 10 interventions
Group B: Empiric antimicrobial prophylaxisActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Infection-related readmission rate

The rate of readmissions where the main cause of readmission is symptoms of infection.

Time frame
90 days after surgery

Secondary outcomes

1

Postoperative complications

Postoperative complications using the validated Clavien-Dindo classification score, ranging from 1-5 where 1-2 are minor complications and 3-5 are major complications.

Time frame
30 and 90 days after surgery
2

Postoperative readmissions

All-cause postoperative readmissions, including the the main cause, timing, and duration.

Time frame
30 and 90 days after surgery
3

Days alive and out of hospital

The number of days that the participants are alive and not admitted to the hospital.

Time frame
30 and 90 days after surgery
4

Quality of life

Quality-of-life using the validated European Organisation of Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30). Results will be presented as scores ranging from 0-100 where high scores in the global health status and functional scales represent a better quality of life and high scores in the symptom scales represent a high level of symptomatology.

Time frame
90 days after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.